Differential changes in GPR55 during microglial cell activation

FEBS Letters

Volumn 583, Issue 12, 2009, Pages 2071-2076

  Pietr, Maciej ^a   Kozela, Ewa ^a   Levy, Rivka ^a   Rimmerman, Neta ^a   Lin, Yi Hsing ^b   Stella, Nephi ^b   Vogel, Zvi ^a,c   Juknat, Ana ^c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cannabinoid; CB2 receptor; ERK phosphorylation; G protein coupled receptor 55; Interferon gamma; Lipopolysaccharide; Lysophosphatidylinositol; Microglia

Indexed keywords

CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; INFLAMMATION; MICROGLIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; BASE SEQUENCE; CELL LINE; CELLS, CULTURED; DNA PRIMERS; GENE EXPRESSION; INTERFERON-GAMMA, RECOMBINANT; LIPOPOLYSACCHARIDES; LYSOPHOSPHOLIPIDS; MICE; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RECEPTORS, CANNABINOID; RNA, MESSENGER;

EID: 67349196005     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.05.028     Document Type: Article

References (35)

1. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5 (2005) 400-411
2. Nah S.Y., Saya D., and Vogel Z. Cannabinoids inhibit agonist-stimulated formation of inositol phosphates in rat hippocampal cultures. Eur. J. Pharmacol. 246 (1993) 19-24
3. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., Liu J., and Kunos G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106 (2005) 133-145
4. Matas D., Juknat A., Pietr M., Klin Y., and Vogel Z. Anandamide protects from low serum induced apoptosis via its degradation to ethanolamine. J. Biol. Chem. 282 (2007) 7885-7892
5. Kreitzer F.R., and Stella N. The therapeutic potential of novel cannabinoid receptors. Pharmacol. Ther. 122 (2009) 83-96
6. Sawzdargo M., Nguyen T., Lee D.K., Lynch K.R., Cheng R., Heng H., George S.R., and O'Dowd B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, GPR53 and GPR55: GPR55 is extensively expressed in human brain. Mol. Brain Res. 64 (1999) 193-198
7. Baker D., Pryce G., Davies W.L., and Robin Hiley C. In silico patent searching reveals a new cannabinoid receptor. TIBS 27 (2006) 1-4
8. Ross R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 30 (2009) 156-163
9. Johns D.G., Behm D.J., Walker D.J., Ao Z., Shapland E.M., Daniels D.A., Riddick M., Dowell S., Staton P.C., Green P., Shabon U., Bao W., Aiyar N., Yue T.L., Brown A.J., Morrison A.D., and Douglas S.A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Brit. J. Pharmacol. 152 (2007) 825-831
10. Ryberg E., Larsson N., Sjögren S., Hjorth S., Hermansson N.-O., Leonova J., Elebring T., Nilsson K., Drmota T., and Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Brit. J. Pharmacol. 152 (2007) 1092-1101
11. 2+ signaling and NFAT activation. FASEB J. 23 (2008) 183-193
12. Lauckner J.E., Jensen J.B., Chen H.-Y., Lu H.-C., Hille B., and Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. PNAS 105 (2008) 2699-2704
13. Oka S., Toshida T., Maruyama K., Nakajima K., Yamashita A., and Sugiura T. 2-Arachidonoyl-sn-glycero-3phosphoinositol: a possible natural ligand for GPR55. J. Biochem. 145 (2009) 13-20
14. Walter L., and Stella N. Cannabinoids and neuroinflammation. Brit. J. Pharmacol. 141 (2004) 775-785
15. 2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev. Mol. Med. 11 e3 (2009) 1-25
16. Puffenbarger R.A., Boothe C., and Cabral G.A. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29 (2000) 58-69
17. Staton P.C., Hatcher J.P., Walker D.J., Morrison A.D., Shapland E.M., Hughes J.P., Chong E., Mander P.K., Green P., Billinton A., Fulleylove M., Lancaster H.C., Smith J.C., Bailey L.T., Wise A., Brown A.J., Richardson J.C., and Chessell I.P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139 (2008) 225-236
18. Hanisch U.K., and Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10 (2007) 1387-1394
19. Pertwee R.G. Cannabinoids and multiple sclerosis. Pharmacol. Ther. 95 (2002) 165-174
20. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., and de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005) 1904-1913
21. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav. Immun. 17 (2003) 13-19
22. 2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2 (2002) 69-82
23. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., and Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23 (2003) 1398-1405
24. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology 56 (2009) 244-253
25. 1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther. 288 (1999) 1357-1366
26. 2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem. 95 (2005) 437-445
27. 2 receptors in the brain: role in central immune function. Brit. J. Pharmacol. 153 (2008) 240-251
28. 2 cannabinoid receptor signaling during neuropathic pain. J. Neurosci. 28 (2008) 12136-12145
29. Walter L., Franklin A., Witting A., Moller T., and Stella N. Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem. 277 (2002) 20869-20876
30. 9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas. Mol. Cell Neurosci. 31 (2006) 795-804
31. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acid Res. 29 (2001) E45
32. Kraus S., Benard O., Naor Z., and Seger R. c-Src is activated by the epidermal growth factor receptor in a pathway that mediates JNK and ERK activation by gonadotrophin-releasing hormone in COS7 cells. J. Biol. Chem. 278 (2003) 32618-32630
33. 1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem. Pharmacol. 53 (1997) 207-214
34. Park J.-S., Lee E.-J., Le J.-C., Kim W.-K., and Kim H.-S. Anti-inflammatory effects of short chain fatty acids in IFN-γ-stimulated RAW 264.7 murine macrophage cells: involvement of NF-κB and ERK signaling pathways. Int. Immunopharmacol. 7 (2007) 70-77
35. Becher B., and Antel J.P. Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia 18 (1996) 1-10